Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer
Dongfeng Qu,Nathaniel Weygant,Jiannan Yao,Parthasarathy Chandrakesan,William L. Berry,Randal May,Kamille Pitts,Sanam Husain,Stan Lightfoot,Min Li,Timothy C. Wang,Guangyu An,Cynthia Clendenin,Ben Z. Stanger,Courtney W. Houchen,Dongfeng Qu,Nathaniel Weygant,Jiannan Yao,Parthasarathy Chandrakesan,William L. Berry,Randal May,Kamille Pitts,Sanam Husain,Stan Lightfoot,Min Li,Timothy C. Wang,Guangyu An,Cynthia Clendenin,Ben Z. Stanger,Courtney W. Houchen
DOI: https://doi.org/10.1155/2019/6402925
IF: 4.501
2019-08-05
Journal of Oncology
Abstract:Oncogenic KRAS mutation plays a key role in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis with nearly 95% of PDAC harboring mutation-activated KRAS, which has been considered an undruggable target. Doublecortin-like kinase 1 (DCLK1) is often overexpressed in pancreatic cancer, and recent studies indicate that DCLK1+ PDAC cells can initiate pancreatic tumorigenesis. In this study, we investigate whether overexpressing DCLK1 activates RAS and promotes tumorigenesis, metastasis, and drug resistance. Human pancreatic cancer cells (AsPC-1 and MiaPaCa-2) were infected with lentivirus and selected to create stable DCLK1 isoform 2 (alpha-long, AL) overexpressing lines. The invasive potential of these cells relative to vector control was compared using Matrigel coated transwell assay. KRAS activation and interaction were determined by a pull-down assay and coimmunoprecipitation. Gemcitabine, mTOR (Everolimus), PI3K (LY-294002), and BCL-2 (ABT-199) inhibitors were used to evaluate drug resistance downstream of KRAS activation. Immunostaining of a PDAC tissue microarray was performed to detect DCLK1 alpha- and beta-long expression. Analysis of gene expression in human PDAC was performed using the TCGA PAAD dataset. The effects of targeting DCLK1 were studied using xenograft and Pdx 1 C r e Kra s G 12 D Trp5 3 R 172 H / + (KPC) mouse models. Overexpression of DCLK1-AL drives a more than 2-fold increase in invasion and drug resistance and increased the activation of KRAS. Evidence from TCGA PAAD demonstrated that human PDACs expressing high levels of DCLK1 correlate with activated PI3K/AKT/MTOR-pathway signaling suggesting greater KRAS activity. High DCLK1 expression in normal adjacent tissue of PDAC correlated with poor survival and anti-DCLK1 mAb inhibited pancreatic tumor growth in vivo in mouse models.
oncology